Research Paper Volume 11, Issue 9 pp 2583—2609

Long-term every-other-day administration of DMAMCL has little effect on aging and age-associated physiological decline in mice

Figure 1. Effects of DMAMCL treatment on body weight, survival rate, neurobehavioral phenotypes and physical performance. (A) The chemical structure of DMAMCL. (B) A scheme showing the long-term DMAMCL administration and various analyses. DMAMCL treatment was initiated at 54 weeks, and the experiment lasted for 15 months. (C) Body weight. (D) Kaplan-Meier survival curves (n = 23 mice per experimental group x 4 groups: control, 10, 25, and 50 mg/kg/EOD). (E-H) Learning and memory ability was examined in the animals using the Morris water maze (n=12). (E) Latencies to find the platform. (F) The first time to find the platform during the probe trial at day 6. (G) Swimming speed at day 6. (H) Quadrant occupancy during the probe trial. TQ, target quadrant; OQ, other quadrants. (I) Time to fall from an accelerating rotarod (n=8-12). (J and K) Total distance (J) and time (K) ran on treadmill performance (n=9-10). (L and M) Total distance (L) and Duration of movement in the central area (M) in Open-field test (n=13-14 per group). (N) Open/ (open + closed) ratio in Elevated plus maze test (n=14 per group). Data are represented as the mean ± SEM. *P < 0.05 and **P < 0.01 compared with the control group (t-test two tailed).